Sinus Disease and Smell in Young Children With Cystic Fibrosis
Observes sinus disease and smell in children with cystic fibrosis taking modulator drugs.
Key facts
- Who runs it
- University of California, Los Angeles
- Where
- Aurora, Charlottesville, Cincinnati, Colchester, Iowa City, and Kansas City, United StatesSee the 6 sites
- Trial code
- Registry title
- Sinus Disease in Young Children With Cystic Fibrosis
- Status
- Recruiting
- People taking part
- 80 people, planned
- Started
- 12 Apr 2023
- Expected to end
- 30 Jun 2029
- Type of study
- Observational, 2 groups
- Treatments tested
- Ivacaftor or elexacaftor/tezacaftor/ivacaftor
- Record updated
- 10 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children aged 2 to 8 with cystic fibrosis. One group is about to start modulator therapy; the other group is not taking it.
- Age
- 2 to 8 years old at the first study visit
- Sex
- All sexes
- Earlier treatment
- Children in the modulator group must not have used ivacaftor or elexacaftor/tezacaftor/ivacaftor in the 180 days before the first visit.
- Biomarker or test result
- Modulator group: a CFTR mutation that fits the approved use of ivacaftor or elexacaftor/tezacaftor/ivacaftor. Control group: a CFTR mutation that rules out this therapy, or a clinical decision not to start it.
Main reasons for not taking part
- Investigational drug in the 28 days before the first study visit
- Ivacaftor or elexacaftor/tezacaftor/ivacaftor in the 180 days before the first study visit
- Long-term oral corticosteroids in the 28 days before the first study visit
- Sinus surgery in the 180 days before the first study visit
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- HEMT Group:
- Children with documentation of a CF diagnosis
- Age 2-8 years old at first study visit
- CFTR mutation consistent with FDA labeled indication of highly effective modulator therapy (ivacaftor or elexacaftor/tezacaftor/ivacaftor)
- Clinician intent to prescribe ivacaftor or ETI so that enrollment is before start of HEMT; Non-HEMT/Control Group:
- Children with documentation of a CF diagnosis
- Age 2-8 years at first study visit
- Ineligible for highly effective modulator therapy (ivacaftor or elexacaftor/tezacaftor/ivacaftor) based on CFTR mutation or clinical decision not to initiate HEMT if eligible
Who cannot take part
- Use of an investigational drug within 28 days prior to the first study visit
- Use of ivacaftor or elexacaftor/tezacaftor/ivacaftor within the 180 days prior to and including the first study visit
- Use of chronic oral corticosteroids within the 28 days prior to and including the first study visit
- Sinus surgery within 180 days prior to the first study visit
- For Both Groups:
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 8 years old?
Where in United States
- Children's Hospital ColoradoAurora, United StatesContact: Edith Zemanick, MDTaking people
- University of VirginiaCharlottesville, United StatesContact: Jaime Mata, MS, PhDTaking people
- Cincinnati Children's Hospital Medical CenterCincinnati, United StatesContact: Jason Woods, PhDTaking people
- University of VermontColchester, United StatesContact: Jillian S Sullivan, MDTaking people
- University of IowaIowa City, United StatesContact: Sean B Fain, PhDTaking people
- University of Kansas Medical CenterKansas City, United StatesContact: Michael Lewis, MDTaking people
About the trial
What the trial wants to find out
This is a prospective, observational study examining the impact of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators on chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) in young children with cystic fibrosis (YCwCF). This study involves two groups: children 2-8 years old, inclusive at initial visit, receiving highly effective modulator therapy (HEMT), and a control group of children 2-8 years old, inclusive at initial visit, not receiving HEMT. Outcomes will include sinus magnetic resonance imaging (MRI) scans, olfactory tests, and quality of life surveys obtained over a two-year period.
The 2 groups in the trial
- HEMT Group
Children with CF planning to start ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy. Participants from the non-HEMT group of this study may enroll into the HEMT cohort if they become eligible for these CFTR modulator therapies and plan to start them.
Treatment: Ivacaftor or elexacaftor/tezacaftor/ivacaftor
- Non-HEMT/Control Group
Children with CF not on ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Sinus Disease in Young Children With Cystic Fibrosis
- Plain-language title
- Sinus Disease and Smell in Young Children With Cystic FibrosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06191640, who can take part
- Publications
- Record updated
- 10 September 2026